FDA Approves Priority Review of Merck&#x27;s Zolinza (Vorinostat)

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Leticia Nogueira, PhD, MPH

March 31st 2025

EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

CHMP Grants Positive Opinion to Tislelizumab/Chemo in Front-Line ES-SCLC

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.

EU’s CHMP Recommends Approving Perioperative Nivolumab Combo in NSCLC

Tislelizumab plus chemotherapy demonstrated superior OS, PFS, ORR, and DOR results compared with placebo plus chemotherapy in first-line ES-SCLC.

Related Content

Adjuvant Therapy and Post-Surgical Management Options for Kidney Cancer

Data from the phase 3 CheckMate 77T trial support the CHMP’s opinion on approving the perioperative nivolumab regimen for those with resectable NSCLC.

Manojkumar Bupathi, MD, MS;Benjamin Garmezy, MD

A Staged Approach Offers Benefits Without OS Detriment in Appendix Cancers

A recent Oncology Decoded podcast focuses on adjuvant therapy like pembrolizumab and optimal post-surgical care for patients with kidney cancer.

Improving NSCLC Surgery Recovery After Climate Disaster Exposure

Muhammad Talwa Waheed, MD, found that resection after appendectomy should be prioritized in the treatment of patients with appendiceal cancer.

Leticia Nogueira, PhD, MPH

March 31st 2025

EU’s CHMP Has Positive Opinion for Subcutaneous Nivolumab in Solid Tumors

The “inescapability” of climate hazards may necessitate prioritization of research to improve outcomes among vulnerable populations who require treatment.

CHMP Grants Positive Opinion to Tislelizumab/Chemo in Front-Line ES-SCLC

Data from the phase 3 CheckMate-67T trial support the CHMP’s recommendation for approving subcutaneous nivolumab across various solid tumor indications.